Tau aggregates as immunotherapeutic targets - PubMed (original) (raw)
Review
. 2013 Jan 1;5(2):426-38.
doi: 10.2741/s381.
Affiliations
- PMID: 23277060
- DOI: 10.2741/s381
Free article
Review
Tau aggregates as immunotherapeutic targets
Diana L Castillo-Carranza et al. Front Biosci (Schol Ed). 2013.
Free article
Abstract
Pathological aggregation of the microtubule-associated protein tau and accumulation of neurofibrillary tangles (NFT) and other inclusions containing hyperphosphorylated tau are defining histopathological features of Alzheimer disease (AD) and many other neurodegenerative diseases collectively known as tauopathies. The toxicity of tau aggregates has been demonstrated in vitro and in vivo; thus, their clearance by immunotherapy holds clinical promise. Published studies, which are limited in number, have exclusively focused on the clearance of hyperphosphorylated large tau aggregates, e.g., NFT. However, recent studies using human tissues and mouse models have questioned the toxicity and the presumed role of NFT in the progression of tauopathies and challenged the view of tangles as toxic species in the brain. Together, these novel studies have demonstrated that prefilamentous tau oligomers rather than NFT play a crucial role in these disorders. Here, we summarize recent advances in this new field, highlight the role of tau oligomers and their potential as a therapeutic target for the treatment of AD and other neurodegenerative tauopathies, and discuss the challenges that lie ahead.
Similar articles
- Tau oligomers as potential targets for immunotherapy for Alzheimer's disease and tauopathies.
Lasagna-Reeves CA, Castillo-Carranza DL, Jackson GR, Kayed R. Lasagna-Reeves CA, et al. Curr Alzheimer Res. 2011 Sep;8(6):659-65. doi: 10.2174/156720511796717177. Curr Alzheimer Res. 2011. PMID: 21605039 Review. - Anti-tau oligomers passive vaccination for the treatment of Alzheimer disease.
Kayed R. Kayed R. Hum Vaccin. 2010 Nov;6(11):931-5. doi: 10.4161/hv.6.11.12689. Epub 2010 Nov 1. Hum Vaccin. 2010. PMID: 20980799 Review. - Immunotherapy for Alzheimer's disease.
Wang W, Fan L, Xu D, Wen Z, Yu R, Ma Q. Wang W, et al. Acta Biochim Biophys Sin (Shanghai). 2012 Oct;44(10):807-14. doi: 10.1093/abbs/gms065. Epub 2012 Aug 16. Acta Biochim Biophys Sin (Shanghai). 2012. PMID: 22899646 Review. - Identification of oligomers at early stages of tau aggregation in Alzheimer's disease.
Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Sarmiento J, Troncoso J, Jackson GR, Kayed R. Lasagna-Reeves CA, et al. FASEB J. 2012 May;26(5):1946-59. doi: 10.1096/fj.11-199851. Epub 2012 Jan 17. FASEB J. 2012. PMID: 22253473 Free PMC article. - Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles.
Castillo-Carranza DL, Sengupta U, Guerrero-Muñoz MJ, Lasagna-Reeves CA, Gerson JE, Singh G, Estes DM, Barrett AD, Dineley KT, Jackson GR, Kayed R. Castillo-Carranza DL, et al. J Neurosci. 2014 Mar 19;34(12):4260-72. doi: 10.1523/JNEUROSCI.3192-13.2014. J Neurosci. 2014. PMID: 24647946 Free PMC article.
Cited by
- The interrelationship of proteasome impairment and oligomeric intermediates in neurodegeneration.
Deger JM, Gerson JE, Kayed R. Deger JM, et al. Aging Cell. 2015 Oct;14(5):715-24. doi: 10.1111/acel.12359. Epub 2015 Jun 5. Aging Cell. 2015. PMID: 26053162 Free PMC article. Review. - Long-Term Consequences of Traumatic Brain Injury: Current Status of Potential Mechanisms of Injury and Neurological Outcomes.
Bramlett HM, Dietrich WD. Bramlett HM, et al. J Neurotrauma. 2015 Dec 1;32(23):1834-48. doi: 10.1089/neu.2014.3352. Epub 2014 Dec 19. J Neurotrauma. 2015. PMID: 25158206 Free PMC article. Review. - A generic method for design of oligomer-specific antibodies.
Brännström K, Lindhagen-Persson M, Gharibyan AL, Iakovleva I, Vestling M, Sellin ME, Brännström T, Morozova-Roche L, Forsgren L, Olofsson A. Brännström K, et al. PLoS One. 2014 Mar 11;9(3):e90857. doi: 10.1371/journal.pone.0090857. eCollection 2014. PLoS One. 2014. PMID: 24618582 Free PMC article. - Protein phosphorylation in neurodegeneration: friend or foe?
Tenreiro S, Eckermann K, Outeiro TF. Tenreiro S, et al. Front Mol Neurosci. 2014 May 13;7:42. doi: 10.3389/fnmol.2014.00042. eCollection 2014. Front Mol Neurosci. 2014. PMID: 24860424 Free PMC article. Review. - Immunotherapy for the treatment of Alzheimer's disease: amyloid-β or tau, which is the right target?
Castillo-Carranza DL, Guerrero-Muñoz MJ, Kayed R. Castillo-Carranza DL, et al. Immunotargets Ther. 2013 Dec 27;3:19-28. doi: 10.2147/ITT.S40131. eCollection 2014. Immunotargets Ther. 2013. PMID: 27471697 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical